Revtorpyk Patent Expiration

Revtorpyk is a drug owned by Celcuity Inc. It is protected by 7 US drug patents filed in 2026 out of which none have expired yet. Revtorpyk's patents will be open to challenges from 14 July, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 31, 2042. Details of Revtorpyk's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8039469 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors
Dec, 2029

(3 years from now)

Active
US9174963 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors
May, 2029

(2 years from now)

Active
US8575159 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors
May, 2029

(2 years from now)

Active
US8748421 Triazine Compounds As P13 Kinase And Mtor Inhibitors
May, 2029

(2 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12350276 Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea
Aug, 2042

(15 years from now)

Active
US12109308 Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea
Jan, 2041

(14 years from now)

Active
US8217036 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors
May, 2029

(2 years from now)

Active


FDA has granted several exclusivities to Revtorpyk. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Revtorpyk, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Revtorpyk.

Exclusivity Information

Revtorpyk holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Revtorpyk's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 14, 2031

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Revtorpyk is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Revtorpyk's family patents as well as insights into ongoing legal events on those patents.

Revtorpyk's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Revtorpyk's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 31, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Revtorpyk Generics:

There are no approved generic versions for Revtorpyk as of now.





About Revtorpyk

Revtorpyk is a drug owned by Celcuity Inc. Revtorpyk uses Gedatolisib as an active ingredient. Revtorpyk was launched by Celcuity in 2026.

Approval Date:

Revtorpyk was approved by FDA for market use on 14 July, 2026.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Revtorpyk is 14 July, 2026, its NCE-1 date is estimated to be 14 July, 2030.

Active Ingredient:

Revtorpyk uses Gedatolisib as the active ingredient. Check out other Drugs and Companies using Gedatolisib ingredient

Dosage:

Revtorpyk is available in powder form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
180MG/VIAL POWDER Prescription INTRAVENOUS